Abstract:Background: Studies have shown that ERBB3 mutations are associated with poor clinical prognosis by increasing the rate of metastasis and recurrence in many cancers. ERBB3 targeted therapeutics can be effective against ERBB3 mutant-driven tumors. ERBB signal pathway plays a very important role in the initiation and progression of gastric cancer, however the ERBB2 expression and mutation rate is relative low especially in gastric SRCC. Thus, ERBB3 might be a promising target for the treatment in SRCC patients. The aim of this study is to speculate the prognostic and targeted therapy value in gastric SRCC by evaluating the mutation rate and type of ERBB3. Methods: 92 patients with histological diagnosis of advanced gastric SRCC were retrospectively selected for this study. ERBB3 mutation was evaluated by next generation sequencing from formalin-fixed paraffin-embedded (FFPE) samples. ERBB2 expression was tested by immunohistochemistry. Correlations between ERBB2/3 status and clinical pathologic characteristics and overall survival (OS) were performed. Results: All of the 92 patients were diagnosed as local advanced or metastatic gastric SRCC (92.4% were stage III, 7.6% were stage IV). All the patients received 5-FU-based first-line chemotherapy. 14 out of all 92 patients were ERBB3 mutated SRCC, 12 of all the 14 mutations were in the extracellular domain, 2 were in the transmembrane region. There was no correlation between ERBB3 mutation and serosa invasion (P = 0.389) or lymph node metastasis (P = 1.000). The median OS was 20.5 months (95% CI = 10.05to 30.95 months) for patients with ERBB3 mutation, and 19.0 months (95% CI = 15.54 to 22.46 months) for patients without ERBB3 mutation (P = 0.567). There was no difference in OS according to HER2 positive or negative in ERBB3 mutated patients (14.8 months vs 20.5 month, P = 0.374). Conclusions: Our study demonstrated 15.2% of gastric SRCC patients harboring ERBB3 mutation, providing a potential subgroup of gastric SRCC for targeted treatment on ERBB pathway. No difference of OS was observed, probably due to the relative small sample size and low ERBB2 positive rate in SRCC patients. Further investigation on ERBB3 is warranted to clarify mechanisms of ERBB pathway in gastric SRCC. Legal entity responsible for the study: The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing 210008, China Funding: None Disclosure: All authors have declared no conflicts of interest.

Erbb Pathway Alterations In Advanced Gastric Signet-Ring Cell Carcinoma (Srcc) And The Implications For Targeted Therapy.

ERBB3 Mutations in Advanced Gastric Signet-Ring Cell Carcinoma (SRCC) and the Implications for Targeted Therapy

Targeted-sequencing and Comprehensive Molecular Profiling of Gastric Signet Ring Cell Carcinoma

Overexpression of ERα Inhibits Proliferation and Invasion of MKN28 Gastric Cancer Cells by Suppressing Β-Catenin

Prognostic Role of Estrogen Receptor Α and Estrogen Receptor Β in Gastric Cancer

Estrogen Receptor Beta Prevents Signet Ring Cell Gastric Carcinoma Progression in Young Patients by Inhibiting Pseudopodia Formation Via the Mtor–arpc1b/evl Signaling Pathway

Clinical Correlates and Prognostic Value of Different Metastatic Sites in Gastric and Colorectal Signet Ring Cell Carcinoma

Gastrointestinal Signet Ring Cell Malignancy: Current Advancement and Future Prospects

Evaluation Of Driver Mutations Involving In Ras-Raf/Pi3k-Mtor Pathway In Gastric Signet Ring Cell Carcinoma.

P-054 Evaluation of Driver Mutations Involving in RAS-RAF/PI3K-mToR Pathway in Gastric Signet Ring Cell Carcinoma

Abstract 3177: KRAS Gene Status in Gastric Signet-Ring Cell Carcinoma Patients and Act As Biomarker of MEK Inhibitor

ERCC1, RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced Non-Small Cell Lung Cancer.

Tumor Characteristics Associated with Lymph Node Metastasis and Prognosis in Patients with ERBB2-Positive Gastric Cancer

[Advances in the research of gastric signet ring cell carcinoma]

The PD-1, PD-L1 Expression and CD3+ T Cell Infiltration in Relation to Outcome in Advanced Gastric Signet-Ring Cell Carcinoma, Representing a Potential Biomarker for Immunotherapy

Immunosuppressive tumor microenvironment in gastric signet-ring cell carcinoma

Expression of ERCC1 and BRCA1 Predict the Clinical Outcome of Non-Small Cell Lung Cancer in Patients Receiving Platinum-Based Chemotherapy.

Cross-Database Analysis Reveals Sensitive Biomarkers for Combined Therapy for ERBB2+ Gastric Cancer.

Clinicopatho logical features and prognostic analysiso f pait ents with signet ring cle l gastir c carcinoma

Gastric Signet Ring Cell Carcinoma: Current Management and Future Challenges.

[Clinicopathological Features and Prognostic Analysis of Patients with Signet Ring Cell Gastric Carcinoma].